BioHarvest Sciences (NASDAQ:BHST) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Key Points

• BioHarvest Sciences reported a loss of ($0.15) earnings per share for the quarter, missing estimates by ($0.04).
• The company's stock increased by 0.7% to reach $8.82, with a market cap of $144.82 million.
• Craig Hallum initiated coverage with a "buy" rating and set a price target of $15.00 for BioHarvest Sciences.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) posted its earnings results on Monday. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.04), Zacks reports. The firm had revenue of $8.52 million during the quarter, compared to the consensus estimate of $8.53 million. BioHarvest Sciences had a negative net margin of 39.95% and a negative return on equity of 11,357.84%. BioHarvest Sciences updated its Q3 2025 guidance to EPS.

BioHarvest Sciences Stock Performance

Shares of BHST stock traded down $0.25 on Friday, hitting $8.97. The company had a trading volume of 2,782 shares, compared to its average volume of 15,135. The firm has a market cap of $147.29 million, a P/E ratio of -12.81 and a beta of 0.68. The stock's 50-day moving average is $7.36 and its two-hundred day moving average is $6.43. BioHarvest Sciences has a twelve month low of $4.66 and a twelve month high of $9.64.

Analyst Upgrades and Downgrades

Separately, Craig Hallum initiated coverage on BioHarvest Sciences in a research note on Monday, May 5th. They issued a "buy" rating and a $15.00 price target for the company.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.